vs
Lantheus Holdings, Inc.（LNTH）与MYRIAD GENETICS INC（MYGN）财务数据对比。点击上方公司名可切换其他公司
Lantheus Holdings, Inc.的季度营收约是MYRIAD GENETICS INC的1.9倍（$406.8M vs $209.8M）。Lantheus Holdings, Inc.同比增速更快（4.0% vs -0.4%）。过去两年Lantheus Holdings, Inc.的营收复合增速更高（4.9% vs 1.9%）
Lantheus Holdings是一家全球性医疗保健企业，专注于研发、生产及商业化创新诊断显像剂与相关解决方案，产品覆盖肿瘤学、心脏病学、泌尿学等核心医疗领域，主要市场遍及北美及全球其他重点地区。
麦利亚德基因公司是总部位于美国犹他州盐湖城的美国基因检测与精准医疗企业。公司拥有多项自主专利技术，帮助医生与患者了解人类疾病的遗传基础，以及基因在疾病发生、发展和治疗中发挥的作用，相关成果可用于开发评估患病风险、指导疾病诊疗的新产品。
LNTH vs MYGN — 直观对比
营收规模更大
LNTH
是对方的1.9倍
$209.8M
营收增速更快
LNTH
高出4.4%
-0.4%
两年增速更快
LNTH
近两年复合增速
1.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $406.8M | $209.8M |
| 净利润 | $54.1M | — |
| 毛利率 | 59.2% | 70.0% |
| 营业利润率 | 19.0% | -2.7% |
| 净利率 | 13.3% | — |
| 营收同比 | 4.0% | -0.4% |
| 净利润同比 | 558.8% | — |
| 每股收益（稀释后） | $0.86 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LNTHMYGN
| Q4 25 | $406.8M | $209.8M | ||
| Q3 25 | $384.0M | $205.7M | ||
| Q2 25 | $378.0M | $213.1M | ||
| Q1 25 | $372.8M | $195.9M | ||
| Q4 24 | $391.1M | $210.6M | ||
| Q3 24 | $378.7M | $213.3M | ||
| Q2 24 | $394.1M | $211.5M | ||
| Q1 24 | $370.0M | $202.2M |
净利润LNTHMYGN
| Q4 25 | $54.1M | — | ||
| Q3 25 | $27.8M | $-27.4M | ||
| Q2 25 | $78.8M | $-330.5M | ||
| Q1 25 | $72.9M | $-100.0K | ||
| Q4 24 | $-11.8M | — | ||
| Q3 24 | $131.1M | $-22.1M | ||
| Q2 24 | $62.1M | $-36.7M | ||
| Q1 24 | $131.1M | $-26.0M |
毛利率LNTHMYGN
| Q4 25 | 59.2% | 70.0% | ||
| Q3 25 | 57.9% | 69.9% | ||
| Q2 25 | 63.8% | 71.2% | ||
| Q1 25 | 63.8% | 68.5% | ||
| Q4 24 | 63.5% | 71.7% | ||
| Q3 24 | 63.9% | 70.2% | ||
| Q2 24 | 64.9% | 69.6% | ||
| Q1 24 | 65.4% | 68.1% |
营业利润率LNTHMYGN
| Q4 25 | 19.0% | -2.7% | ||
| Q3 25 | 11.4% | -11.3% | ||
| Q2 25 | 23.3% | -154.5% | ||
| Q1 25 | 27.4% | -14.8% | ||
| Q4 24 | 29.1% | -18.6% | ||
| Q3 24 | 35.3% | -9.4% | ||
| Q2 24 | 26.1% | -17.3% | ||
| Q1 24 | 28.8% | -13.8% |
净利率LNTHMYGN
| Q4 25 | 13.3% | — | ||
| Q3 25 | 7.2% | -13.3% | ||
| Q2 25 | 20.8% | -155.1% | ||
| Q1 25 | 19.6% | -0.1% | ||
| Q4 24 | -3.0% | — | ||
| Q3 24 | 34.6% | -10.4% | ||
| Q2 24 | 15.8% | -17.4% | ||
| Q1 24 | 35.4% | -12.9% |
每股收益（稀释后）LNTHMYGN
| Q4 25 | $0.86 | $-0.09 | ||
| Q3 25 | $0.41 | $-0.29 | ||
| Q2 25 | $1.12 | $-3.57 | ||
| Q1 25 | $1.02 | $0.00 | ||
| Q4 24 | $-0.18 | $-0.47 | ||
| Q3 24 | $1.79 | $-0.24 | ||
| Q2 24 | $0.88 | $-0.41 | ||
| Q1 24 | $1.87 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $359.1M | $149.6M |
| 总债务越低越好 | $568.7M | $119.9M |
| 股东权益账面价值 | $1.1B | $368.0M |
| 总资产 | $2.2B | $706.6M |
| 负债/权益比越低杠杆越低 | 0.52× | 0.33× |
8季度趋势，按日历期对齐
现金及短期投资LNTHMYGN
| Q4 25 | $359.1M | $149.6M | ||
| Q3 25 | $382.0M | $145.4M | ||
| Q2 25 | $695.6M | $74.4M | ||
| Q1 25 | $938.5M | $91.8M | ||
| Q4 24 | $912.8M | $102.4M | ||
| Q3 24 | $866.4M | $99.9M | ||
| Q2 24 | $757.0M | $97.3M | ||
| Q1 24 | $718.3M | $104.3M |
总债务LNTHMYGN
| Q4 25 | $568.7M | $119.9M | ||
| Q3 25 | $567.9M | $119.5M | ||
| Q2 25 | $566.8M | — | ||
| Q1 25 | $566.1M | — | ||
| Q4 24 | $565.3M | — | ||
| Q3 24 | $613.0K | — | ||
| Q2 24 | $563.2M | — | ||
| Q1 24 | $562.5M | — |
股东权益LNTHMYGN
| Q4 25 | $1.1B | $368.0M | ||
| Q3 25 | $1.1B | $372.8M | ||
| Q2 25 | $1.2B | $388.1M | ||
| Q1 25 | $1.2B | $704.9M | ||
| Q4 24 | $1.1B | $701.1M | ||
| Q3 24 | $1.2B | $731.7M | ||
| Q2 24 | $1.0B | $740.5M | ||
| Q1 24 | $945.5M | $760.0M |
总资产LNTHMYGN
| Q4 25 | $2.2B | $706.6M | ||
| Q3 25 | $2.3B | $728.1M | ||
| Q2 25 | $2.1B | $677.3M | ||
| Q1 25 | $2.1B | $1.0B | ||
| Q4 24 | $2.0B | $1.0B | ||
| Q3 24 | $2.0B | $1.1B | ||
| Q2 24 | $1.9B | $1.1B | ||
| Q1 24 | $1.8B | $1.1B |
负债/权益比LNTHMYGN
| Q4 25 | 0.52× | 0.33× | ||
| Q3 25 | 0.51× | 0.32× | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.59× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $90.2M | $10.6M |
| 自由现金流经营现金流 - 资本支出 | $81.4M | — |
| 自由现金流率自由现金流/营收 | 20.0% | — |
| 资本支出强度资本支出/营收 | 2.2% | — |
| 现金转化率经营现金流/净利润 | 1.67× | — |
| 过去12个月自由现金流最近4个季度 | $354.1M | — |
8季度趋势，按日历期对齐
经营现金流LNTHMYGN
| Q4 25 | $90.2M | $10.6M | ||
| Q3 25 | $105.3M | $21.1M | ||
| Q2 25 | $87.1M | $-13.6M | ||
| Q1 25 | $107.6M | $-16.3M | ||
| Q4 24 | $157.7M | $6.6M | ||
| Q3 24 | $175.1M | $700.0K | ||
| Q2 24 | $84.7M | $2.6M | ||
| Q1 24 | $127.2M | $-18.6M |
自由现金流LNTHMYGN
| Q4 25 | $81.4M | — | ||
| Q3 25 | $94.7M | — | ||
| Q2 25 | $79.1M | — | ||
| Q1 25 | $98.8M | — | ||
| Q4 24 | $141.4M | — | ||
| Q3 24 | $159.3M | — | ||
| Q2 24 | $73.5M | — | ||
| Q1 24 | $119.0M | — |
自由现金流率LNTHMYGN
| Q4 25 | 20.0% | — | ||
| Q3 25 | 24.7% | — | ||
| Q2 25 | 20.9% | — | ||
| Q1 25 | 26.5% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 42.0% | — | ||
| Q2 24 | 18.7% | — | ||
| Q1 24 | 32.2% | — |
资本支出强度LNTHMYGN
| Q4 25 | 2.2% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 4.2% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | 2.2% | — |
现金转化率LNTHMYGN
| Q4 25 | 1.67× | — | ||
| Q3 25 | 3.79× | — | ||
| Q2 25 | 1.11× | — | ||
| Q1 25 | 1.47× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 0.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
MYGN
暂无分部数据
